Why is Moderna stock down today?

Traders Union
All News
Financial News
Moderna slides 4.18% to $78.38 today

Highlights

Moderna’s mRNA-1010 flu vaccine secured unanimous FDA advisory backing for adults 50+, increasing approval prospects after positive Phase 3 results.
The launch of the mRNA-6007 in vivo CAR-T program marks Moderna’s strategic expansion into autoimmune disease and diversifies its pipeline beyond infectious diseases.
MRNA trades in a $70.92–$85.84 range with bullish mid- and long-term trends, but short-term selling pressure and high volatility persist despite strong momentum signals.

Regulatory momentum and pipeline expansion buoy sentiment despite selling pressure

Moderna’s investigational mRNA-1010 influenza vaccine received unanimous support from the FDA advisory committee for its benefit-risk profile in adults aged 50 and older, based on Phase 3 data involving over 40,000 participants, according to Mondaq. This outcome improves the likelihood of regulatory approval for the vaccine and showcases Moderna’s ability to advance late-stage products targeting broad patient populations. Additionally, Moderna introduced a new in vivo CAR-T program, mRNA-6007, aimed at autoimmune diseases such as systemic lupus erythematosus, which signals an expansion of its R&D pipeline beyond infectious diseases, as reported by Quiverquant. These developments highlight positive product momentum and regulatory progress, though price action has remained under broader selling pressure.

Momentum signals diverge from price near key support zones

On the hourly chart, MRNA is trading below its MA-20 at $78.45 but remains above the MA-50 at $71.59, and holds well above the long-term MA-200 at $41.40 on the daily timeframe. Immediate support is indicated near the Ichimoku Kijun level at $77.27. The Moving Average Convergence Divergence (MACD) is currently on a 'Strong Buy' signal, and the Average Directional Index (ADX) also reflects a 'Buy' reading, suggesting strong intraday momentum. The Relative Strength Index (RSI) stands at 68.14 ('Buy'), the Commodity Channel Index (CCI) registers another 'Buy', while the Stochastic RSI is in 'Oversold' territory and Bull/Bear Power is 'Overbought', highlighting the risk of a short-term reversal as buyers dominate intraday. The Awesome Oscillator is neutral, and the stock closed with a slight gap of 0.17 and trades close to today's low amid elevated volatility, creating a divergence between momentum and recent price direction.

Sideways outlook with volatility and asymmetric upside probabilities

Over the next few sessions, MRNA is expected to trade within a volatility band of $70.92 to $85.84. The probability of an upward move stands at 76%, while the downside is less likely at 24%. The baseline scenario is for sideways price action within this range. A move above resistance could trigger further advances, whereas a decisive break below support may lead to accelerated declines.

Anton Kharitonov, expert at Traders Union, notes that Moderna has made clear progress with regulatory support for its mRNA-1010 flu vaccine and has expanded its pipeline into autoimmune diseases. However, he sees that the stock remains under short-term downside pressure despite positive news flow and strong readings from intraday technical indicators. The analyst remains cautious, expecting sideways action unless $77.27 support is breached. "Until $77.27 fails, I remain defensive and see no compelling risk-reward for new positions here."

Earlier, analysts noted that Moderna's stock recovery was driven by technical momentum and positive sentiment around its expanding drug pipeline. New regulatory progress and pipeline updates now add fundamental support to the bullish case, but elevated volatility means traders should closely monitor the $70.92–$85.84 range as the next test of directional conviction.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.